1st Speaker

Move!  Exploring the Role of Physical Activity as a Treatment for Depression in Adolescents

Daniel Hosker, M.D.

2nd Speaker

Gabapentin Protocol and Management of Alcohol Withdrawal Syndrome

Daniela Rakocevic, M.D.

Introduction

1st Speaker
Daniel Hosker, MD, grew up in Plymouth, Minnesota. He received his B.A. from the University of Minnesota, where he started majoring in aerospace engineering and mechanics, though switched to physiology when he decided to pursue medicine. He went on to obtain his MD from Creighton University School of Medicine. He is currently in his fourth year of the psychiatry residency program at the Mayo Clinic. He will be starting child and adolescent fellowship at MGH/McLean in July 2018.

2nd Speaker
Dr. Daniela Rakocevic graduated from University of Belgrade Medical School, summa cum laude, where she received her Master of Science degree in Psychiatry and completed residency in Adult Psychiatry. As a BC psychiatrist at the Clinical Center of Serbia she focused on medical and consult liaison psychiatry, as well as medical education. Dr. Rakocevic is currently in her 4th year of the psychiatry training at the Mayo Clinic, where she serves as an Administrative Chief resident. She is an instructor in psychiatry recognized in 2017 with Golden Stethoscope Award for excellence in teaching. Dr. Rakocevic continues to pursue her passion for addiction and consult liaison psychiatry and is excited to start her fellowship in Addiction Psychiatry at the Mayo Clinic.

Learning Objectives

1st Speaker

1. Understand the role of brain-derived neurotrophic factor (BDNF) in depressive-like behavior in rat models
2. Describe how to interpret standardized mean difference (SMD) in research.
3. Describe the evidence for physical activity as a treatment for depression in adolescents

2nd Speaker

1. Review different protocols for the management of alcohol withdrawal syndrome (AWS).
2. Recognize advantages and disadvantages of benzodiazepine versus gabapentin (benzodiazepine sparing) protocol for treatment of AWS. 
3. Describe current evidence for the use of gabapentin in the treatment of alcohol use disorder

Live webcast available at: http://videos.mayo.edu/live
1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live. Ethos will be implemented for all post presentation surveys. To document your attendance, please text the code given at the presentation to 507-200-3010. For questions, email rstpsychgr@mayo.edu.

Accreditation Statement

In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

APA
The Department of Psychiatry and Psychology at Mayo Clinic, Rochester, is approved by the American Psychological Association to sponsor continuing education credits for psychologists. The Department of Psychiatry and Psychology at Mayo Clinic, Rochester maintains responsibility for this program and its content.

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

All participants MUST complete the evaluation in order to get CME or APA Credit.

1) Text the CODE announced at the session within 48 hours to (507) 200-3010
2) Login at ce.mayo.edu and go to My Account, My Courses, Registered Courses, click Session title and START to access the required Evaluation.
-or-
Click the START button on that session page.
3) Evaluation must be completed within 2 weeks.

Disclosure Summary
As a Jointly Accredited Provider by ACCME, ACPE, and ANCC, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry:

Mark Frye, M.D. - Mayo Clinic

Grant Support: AssureRx, Janssen R&D, Myriad, Pfizer Consultant: Janssen R&D, Mitsubishi Tanabe Pharma Corp., Myriad Genetics, Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals, Neuralstem, Inc.

CME/Travel: American Physician Institute, CME Outfitters

No relevant financial relationship(s) with industry:
Kriti Gandhi, M.D., Allison Holgerson, Ph.D., Matej Markota, M.D., Charlene Nelson, Reem Shafi, M.B.B.S., Larua Suarez, M.D.

Speakers:  Daniel Hosker, M.D., and Daniela Rakocevic, M.D.

References to off-label usage(s) of pharmaceuticals or instruments in their presentation: NONE